GlassScriptPhysician profile
Rishi A Kumar
NPI 1881036374
$11,137.53
in general payments reported to CMS, 2019-2025
20 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.78 · 2020: $269 · 2021: $649 · 2022: $510 · 2023: $2,514 · 2024: $6,063 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342 · Travel and Lodging: $2,758 · Education: $2,570 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.89 |
| Travel and Lodging | $2,757.67 |
| Education | $2,569.53 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,247.13 | 2023-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,192.86 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,167.98 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $804.11 | 2020-2025 | Ofev, Jascayd, Spiriva Respimat |
| Genzyme Corporation | $523.62 | 2021-2025 | |
| Grifols USA, LLC | $339.10 | 2020-2025 | Prolastin-C Liquid |
| Amgen INC. | $156.48 | 2022-2025 | Tezspire |
| Philips North America LLC | $144.65 | 2020-2022 | |
| Advanced Respiratory, INC | $101.73 | 2020-2021 | |
| Electromed, INC. | $94.72 | 2023-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $75.43 | 2023 | Dupixent |
| Mylan Specialty L.P. | $60.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $54.00 | 2023 | Xarelto |
| Abbvie INC. | $48.81 | 2023-2024 | |
| Pulmonx Corporation | $30.51 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $22.79 | 2024 | Ruconest |
| Olympus America INC. | $21.02 | 2025 | Bovie, Olympus, Hd Camera Head |
| Lilly USA, LLC | $19.81 | 2025 | Mounjaro, Zepbound |
| Insmed, INC. | $16.24 | 2023 | Arikayce |
| Astrazeneca Uk Limited | $15.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.